Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study.
MGMT
Th1/Th2 cytokine ratios
bortezomib
immune checkpoint
recurrent GBM
temozolomide
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
21
03
2020
revised:
02
05
2020
accepted:
13
05
2020
pubmed:
25
6
2020
medline:
22
9
2021
entrez:
25
6
2020
Statut:
ppublish
Résumé
Glioblastoma (GBM) is an aggressive malignant brain tumor where median survival is approximately 15 months after best available multimodal treatment. Recurrence is inevitable, largely due to O Ten patients received intravenous BTZ 1.3 mg/m Sequential BTZ + TMZ therapy was safe and well tolerated. Pain and performance of daily activities had greatest impact on patients' self-reported quality of life and were inversely correlated with Karnofsky performance status. Patients segregated a priori into three groups, where group 1 displayed stable clinical symptoms and/or slower magnetic resonance imaging radiological progression, expanded CD4 Sequential BTZ + TMZ treatment is safe and promotes Th1-driven immunological responses in selected patients with improved clinical outcomes (Clinicaltrial.gov (NCT03643549)).
Sections du résumé
BACKGROUND
Glioblastoma (GBM) is an aggressive malignant brain tumor where median survival is approximately 15 months after best available multimodal treatment. Recurrence is inevitable, largely due to O
METHODS
Ten patients received intravenous BTZ 1.3 mg/m
RESULTS
Sequential BTZ + TMZ therapy was safe and well tolerated. Pain and performance of daily activities had greatest impact on patients' self-reported quality of life and were inversely correlated with Karnofsky performance status. Patients segregated a priori into three groups, where group 1 displayed stable clinical symptoms and/or slower magnetic resonance imaging radiological progression, expanded CD4
CONCLUSION
Sequential BTZ + TMZ treatment is safe and promotes Th1-driven immunological responses in selected patients with improved clinical outcomes (Clinicaltrial.gov (NCT03643549)).
Identifiants
pubmed: 32578964
doi: 10.1002/iid3.315
pmc: PMC7416034
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Drug Combinations
0
Bortezomib
69G8BD63PP
Dacarbazine
7GR28W0FJI
Temozolomide
YF1K15M17Y
Banques de données
ClinicalTrials.gov
['NCT03643549']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
342-359Informations de copyright
© 2020 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Cancers (Basel). 2019 Jul 17;11(7):
pubmed: 31319548
J Clin Oncol. 2005 Oct 1;23(28):7178-87
pubmed: 16192602
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Altern Med Rev. 2003 Aug;8(3):223-46
pubmed: 12946237
Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1195-1203
pubmed: 29722661
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Cancer Chemother Pharmacol. 2012 Feb;69(2):505-14
pubmed: 21850464
Cancer Cell. 2006 Mar;9(3):157-73
pubmed: 16530701
J Clin Pharmacol. 2017 Sep;57(9):1183-1193
pubmed: 28419486
J Immunol. 2000 Sep 1;165(5):2783-9
pubmed: 10946310
J Neurooncol. 2016 Oct;130(1):193-201
pubmed: 27502784
Cancer Res. 1995 Sep 1;55(17):3847-53
pubmed: 7641203
Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4348-53
pubmed: 9113992
Lancet Oncol. 2006 May;7(5):392-401
pubmed: 16648043
Mol Ther. 2013 Mar;21(3):570-9
pubmed: 23319055
J Neuroimmunol. 2013 Nov 15;264(1-2):71-83
pubmed: 24045166
Cell Death Dis. 2012 Oct 18;3:e412
pubmed: 23076220
J Immunol. 1998 Sep 1;161(5):2099-105
pubmed: 9725200
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Br J Cancer. 2019 Oct;121(7):545-555
pubmed: 31413318
Anticancer Res. 2009 Oct;29(10):3741-50
pubmed: 19846904
Clin Dev Immunol. 2012;2012:831090
pubmed: 23133490
J Neurooncol. 2010 Oct;100(1):95-103
pubmed: 20213332
Cancer Res. 2007 Sep 15;67(18):8952-9
pubmed: 17875738
Am J Clin Oncol. 2016 Feb;39(1):98-106
pubmed: 26558876
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
J Neurosurg. 2011 Jun;114(6):1622-30
pubmed: 21314270
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Clin Cancer Res. 2013 Feb 15;19(4):764-72
pubmed: 23209033
Genes Immun. 2004 Dec;5(8):621-30
pubmed: 15573087
Cancer Chemother Pharmacol. 2011 Jan;67(1):57-67
pubmed: 20306195
J Neurooncol. 2015 Oct;125(1):191-5
pubmed: 26285768
J Clin Oncol. 2009 Dec 10;27(35):5874-80
pubmed: 19901110
J Clin Oncol. 2007 Feb 1;25(4):399-404
pubmed: 17264335
Eur J Immunol. 1998 Oct;28(10):3137-43
pubmed: 9808182
J Immunol. 2006 Apr 15;176(8):4757-65
pubmed: 16585569
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):433-9
pubmed: 19084346
Ann Oncol. 2014 Jan;25(1):9-15
pubmed: 24335854
Mol Cancer Ther. 2012 Jun;11(6):1289-99
pubmed: 22532597
Cancer Res. 1996 May 1;56(9):2029-32
pubmed: 8616846
J Immunol. 2012 Sep 15;189(6):3209-20
pubmed: 22896634
J Neurooncol. 2016 Aug;129(1):139-46
pubmed: 27300524
Cell. 2019 Aug 8;178(4):835-849.e21
pubmed: 31327527
J Exp Clin Cancer Res. 1999 Jun;18(2):225-32
pubmed: 10464712
J Neurosurg. 2011 Jul;115(1):3-8
pubmed: 21417701
Prostate. 2000 Sep 1;44(4):271-4
pubmed: 10951490
J Clin Oncol. 2002 May 1;20(9):2277-83
pubmed: 11980998
J Clin Oncol. 2009 Sep 1;27(25):4150-4
pubmed: 19636000
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Cancer Res. 2016 Sep 15;76(18):5326-36
pubmed: 27406829
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Trends Immunol. 2003 Jan;24(1):36-43
pubmed: 12495723
J Biol Chem. 2000 Nov 3;275(44):34197-204
pubmed: 10942771
Nat Rev Immunol. 2017 Sep;17(9):545-558
pubmed: 28580957
Immun Inflamm Dis. 2020 Sep;8(3):342-359
pubmed: 32578964
Health Policy. 1991 Jun;18(1):25-36
pubmed: 10112299
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neuro Oncol. 2017 May 1;19(5):625-635
pubmed: 28453751
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318